List of Excipients in Branded Drug CEFOTETAN AND DEXTROSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFOTETAN AND DEXTROSE	cefotetan and dextrose	0264-3173	DEXTROSE MONOHYDRATE
B Braun Medical Inc	CEFOTETAN AND DEXTROSE	cefotetan and dextrose	0264-3173	WATER

Cefotetan and Dextrose Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 30, 2026

Cefotetan and dextrose injection is a mature generic intravenous cephamycin product. Its commercial value is driven by hospital procurement, supply reliability, premixed delivery, container technology, and antimicrobial-stewardship positioning rather than by conventional small-molecule patent exclusivity. The most attractive opportunities are ready-to-use presentations, preservative-free single-dose packaging, differentiated storage formats, and supply contracts with hospitals and group purchasing organizations.

Cefotetan is administered intravenously for susceptible bacterial infections and for perioperative prophylaxis. Dextrose generally functions as the aqueous vehicle and tonicity-adjusting component. The formulation must control cefotetan degradation, pH drift, particulate formation, container compatibility, and microbial risk during storage and administration.

What is cefotetan and dextrose injection?

Cefotetan and dextrose injection combines cefotetan disodium with a dextrose-containing intravenous vehicle. Cefotetan is a beta-lactam antibacterial in the cephamycin class. The product is administered intravenously and is used for selected infections caused by susceptible gram-positive and gram-negative organisms, as well as surgical prophylaxis in approved indications. FDA labeling identifies cefotetan as a sterile injectable product requiring controlled preparation and administration conditions (U.S. Food and Drug Administration [FDA], 2023a).

Attribute	Commercial relevance
Active ingredient	Cefotetan disodium
Drug class	Cephamycin beta-lactam antibacterial
Route	Intravenous
Dextrose role	Vehicle, carbohydrate source, and tonicity contributor
Typical commercial format	Premixed IV solution or powder for reconstitution, depending on manufacturer
Primary customers	Hospitals, outpatient infusion providers, surgical centers, government buyers
Regulatory category	Generic prescription injectable
Main differentiation levers	Stability, container, ready-to-use format, supply continuity, price

Cefotetan is not a biologic. Biosimilar pathways, interchangeability designations, and biologic patent thickets do not apply. Competition occurs through abbreviated new drug applications, manufacturing capacity, procurement contracts, and product availability.

What excipients are used in cefotetan and dextrose injection?

The core excipient system is intentionally narrow. A typical finished product contains dextrose in water for injection, with cefotetan disodium supplying the drug substance and sodium load.

Dextrose

Dextrose has three formulation functions:

1. It provides the aqueous vehicle.
2. It contributes to solution tonicity.
3. It allows the product to be supplied as a premixed infusion rather than as a powder requiring bedside dilution.

Dextrose concentration must be selected to balance osmolarity, patient tolerability, chemical stability, and compatibility with hospital infusion protocols. Higher dextrose concentrations can increase osmolarity and may limit peripheral administration depending on the final product and institutional policy.

Sodium and cefotetan counterion

Cefotetan is supplied as the disodium salt. The sodium contribution affects labeling, fluid management, and suitability for patients requiring sodium restriction. The formulation must maintain cefotetan in solution without promoting precipitation or excessive degradation.

Water for injection

Water for injection is the primary solvent. It must comply with applicable compendial requirements for sterile parenteral products. The manufacturing process must control endotoxins, bioburden, particulate matter, and container-closure integrity.

pH adjustment

The commercial formulation may use pH adjustment to establish a stability window. Any buffer or pH-adjusting agent must be justified by compatibility and degradation data. A robust formulation normally minimizes unnecessary buffer capacity because additional ionic species can affect cefotetan stability, osmolarity, and container interactions.

Preservatives

A hospital-use cefotetan infusion is generally better positioned as preservative-free, particularly in single-dose or pharmacy-prepared formats. Preservatives can create compatibility, hypersensitivity, neonatal-use, and labeling constraints. A multi-dose presentation would require a separate microbiological and regulatory justification.

Excipient category	Strategic objective	Principal risk
Dextrose	Vehicle, tonicity, ready-to-use delivery	Osmolarity and chemical stability
Water for injection	Sterile solvent	Endotoxin and particulate control
pH adjuster or buffer	Stability control	Ionic effects and compatibility
Preservative, if used	Multi-dose microbial control	Toxicology and clinical-use limitations
Container-contact materials	Shelf-life protection	Adsorption, leachables, and extractables

What formulation patents protect cefotetan and dextrose injection?

The original cefotetan compound and early formulation rights are no longer the principal commercial barriers in the United States. Cefotetan is an established generic active ingredient, and the product is outside the normal period of new-drug exclusivity associated with an innovative antibiotic launch.

Current value is more likely to arise from formulation-specific intellectual property covering:

• Premixed cefotetan concentrations in dextrose.
• Long-term refrigerated or controlled-room-temperature stability.
• Frozen or room-temperature storage systems.
• Flexible polymer containers.
• Dual-chamber or ready-to-activate infusion systems.
• Low-particulate manufacturing processes.
• Specific pH ranges or degradation-control methods.
• Container-closure systems that reduce oxygen or moisture exposure.
• Manufacturing processes for cefotetan dissolution and sterile filtration.

These rights would need to satisfy novelty and non-obviousness requirements over established cefotetan solutions and standard parenteral packaging. A patent directed only to using dextrose as a conventional IV vehicle would face a substantial obviousness challenge unless it shows an unexpected stability or compatibility result.

When does cefotetan lose exclusivity?

Cefotetan has already lost practical small-molecule exclusivity. The commercial market is generic, and hospital buyers generally evaluate the product as a multisource injectable antibiotic rather than as a protected branded therapy.

Exclusivity category	Current commercial position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the ordinary product
Pediatric exclusivity	No current strategic relevance
Patent exclusivity	No apparent blocking estate for the core active ingredient
Biosimilar exclusivity	Not applicable
Generic competition	Established
Main barrier to entry	FDA approval, sterile manufacturing, supply scale, and contracting

An applicant’s practical market protection would come from manufacturing capability, a differentiated presentation, or a supply agreement rather than from the cefotetan molecule itself.

What is the Orange Book status of cefotetan and dextrose?

The Orange Book primarily lists approved drug products and patent or exclusivity information relevant to approved applications. For a mature generic injectable such as cefotetan and dextrose, the key question is whether a current reference-listed drug application has active listed patents or exclusivity that could delay an ANDA.

No widely recognized active Orange Book barrier is associated with the cefotetan molecule. The relevant regulatory work is product-specific: identifying the reference product, confirming the dosage form and route, establishing pharmaceutical equivalence, and demonstrating bioequivalence or the applicable waiver pathway for an injectable solution.

An ANDA strategy should focus on:

• Correct strength and volume.
• Cefotetan disodium equivalence.
• Dextrose concentration.
• pH and osmolality.
• Sterility and bacterial endotoxin limits.
• Particulate matter.
• Container-closure integrity.
• Extractables and leachables.
• In-use stability and dilution compatibility.

FDA product labeling and the Orange Book remain the primary sources for reference-product and approval-status verification (FDA, 2023b; FDA, 2024).

What generic entry risks exist for cefotetan and dextrose?

Generic entry risk is high because the active ingredient is established and the formulation concept is conventional. A new entrant can compete if it can reproduce the reference product’s critical quality attributes and achieve reliable sterile-manufacturing economics.

The principal entry risks are operational rather than patent-based:

Sterile manufacturing failure

Parenteral beta-lactams require stringent control of aseptic processing, endotoxins, particulate matter, and container integrity. A manufacturing site with limited injectable experience may face inspection findings, approval delays, or supply interruptions.

Cefotetan degradation

Cefotetan stability can be affected by pH, temperature, light, oxygen exposure, and storage time. A nominally equivalent formulation may fail if its degradation profile differs from the reference product.

Container interaction

Flexible polymer systems can introduce extractables, leachables, adsorption, or permeability concerns. Glass containers may create breakage and handling issues but can simplify some compatibility assessments.

Hospital substitution limitations

Even when products are therapeutically equivalent, hospitals may restrict substitution based on formulary, infusion-library configuration, packaging, bar-code systems, or contract terms.

How strong is the patent estate for cefotetan and dextrose?

The patent estate is weak for the core drug and potentially meaningful only for narrowly drafted formulation or delivery claims.

Patent layer	Relative strength	Commercial effect
Cefotetan compound	Low	No meaningful current barrier
Basic cefotetan injectable solution	Low to moderate	Depends on claim scope and expiration
Dextrose vehicle concept	Low	Conventional excipient use
Stability-defined formulation	Moderate	Can support differentiated shelf life
Premixed container system	Moderate	May delay direct copying of a package format
Dual-chamber delivery device	Moderate to high	Relevant if clinically and operationally differentiated
Manufacturing process	Moderate	Can protect process economics but is harder to enforce at market level
Trade secret manufacturing controls	Moderate	May protect yield, cycle time, and impurity control

The most defensible intellectual property would combine a narrow formulation claim with a measurable technical result, such as a defined impurity limit after extended storage in a specified container at a specified temperature. Broad claims covering cefotetan in dextrose are less likely to provide durable protection.

What formulation opportunities exist for cefotetan and dextrose?

Ready-to-use premixed bags

The strongest commercial opportunity is a ready-to-use infusion bag that reduces pharmacy compounding. Hospitals value products that reduce preparation steps, improve medication safety, and support barcode administration.

Potential presentations include:

Presentation	Commercial rationale
1 g in 50 mL dextrose solution	Surgical prophylaxis and lower-dose inpatient use
2 g in 50 mL or 100 mL	Treatment and higher-dose administration
Single-dose flexible bag	Reduced compounding and contamination risk
Pharmacy bulk package	Institutional preparation efficiency
Dual-chamber container	Extended shelf life before activation
Small-volume ready-to-use container	Operating-room and emergency-use convenience

Exact strengths and volumes must match the approved reference product and clinical dosing requirements.

Stability-enhanced formulation

A formulation with extended refrigerated or room-temperature stability could create procurement value, particularly for hospitals managing inventory across multiple sites. The product would need a complete degradation, impurity, particulate, and container-compatibility package.

Low-sodium positioning

Cefotetan disodium contributes sodium. A formulation strategy cannot remove the counterion without changing the drug substance, but labeling and concentration choices may support use in patients for whom sodium exposure is clinically relevant. Any such positioning would require quantitative sodium disclosure and approved labeling support.

Closed-system administration

A container compatible with closed-system transfer devices, needleless connectors, and automated infusion pumps could improve workflow. The commercial advantage would be strongest in institutions with standardized infusion systems.

Cold-chain reduction

A product stable at controlled room temperature could reduce distribution and inventory costs. This opportunity is technically demanding because cefotetan degradation may accelerate under thermal stress.

Which companies are challenging the cefotetan market?

Competition is likely to come from generic injectable manufacturers and contract manufacturers with established beta-lactam capabilities. The relevant competitive set includes companies active in hospital injectables, such as Baxter, Hikma, Fresenius Kabi, Pfizer’s Hospira business, Sandoz, and other ANDA holders or authorized distributors, depending on the specific presentation and current supply status.

Competition should be assessed by:

• Current FDA approval status.
• National Drug Code listings.
• Product availability.
• Back-order history.
• Bag versus vial presentation.
• Strength and volume.
• Contract coverage.
• Manufacturing site.
• Recall history.
• API source and supply redundancy.

A company with fewer approved products but reliable supply may be more competitive than a lower-priced supplier with intermittent availability.

What patent litigation and Paragraph IV risks affect cefotetan?

Cefotetan is unlikely to generate significant current Paragraph IV litigation over the core molecule because the product is mature and genericized. A Paragraph IV dispute could still arise around a new formulation, delivery device, stability method, or packaging patent.

Potential litigation theories would include:

• Invalidity based on routine optimization of pH, dextrose concentration, or storage conditions.
• Non-infringement based on different excipients, container materials, or process parameters.
• Lack of written description for broad formulation claims.
• Obviousness over prior cefotetan injectable solutions and standard dextrose vehicles.
• Patent misuse or scope disputes involving a device claim.

A formulation sponsor should avoid relying on a single broad patent. Layered claims covering composition, container, process, and use can create better negotiating leverage, but each layer must have independent technical support.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve manufacturing and distribution than molecule rights.

Manufacturing license

A regional manufacturer could license a validated cefotetan process, container system, or sterile-fill platform. The agreement would have value if it includes technology transfer, analytical methods, impurity standards, and regulatory support.

Distribution agreement

A hospital-injectable supplier may license or distribute an approved product under its own commercial network. The main value drivers are purchasing contracts, government tenders, and supply reliability.

Device collaboration

A premixed or dual-chamber container company could partner with a generic manufacturer. The device partner would contribute packaging intellectual property and development expertise; the drug manufacturer would provide the ANDA and sterile manufacturing infrastructure.

Geographic rights

Cefotetan is a mature antibiotic, so country-specific rights should be evaluated by market access, hospital procurement structure, local GMP requirements, and availability of competing cephamycins. Patent rights are unlikely to determine territory value in most markets.

How does cefotetan compare with competing injectable antibiotics?

Cefotetan competes with other perioperative and broad-spectrum injectable antibiotics. Cefazolin is often favored for common surgical prophylaxis because of established guidelines, familiarity, cost, and narrower spectrum. Cefoxitin and cefotetan may be used where anaerobic coverage or specific institutional protocols support their use. Ceftriaxone and other cephalosporins compete in treatment settings but do not have identical indications or dosing profiles.

Product	Main competitive factor	Commercial implication
Cefotetan	Anaerobic activity and established injectable use	Niche hospital demand
Cefazolin	Low cost and broad surgical-prophylaxis adoption	Strong formulary competition
Cefoxitin	Similar cephamycin positioning	Direct therapeutic substitute in some protocols
Ceftriaxone	Broad use and convenient dosing	Strong treatment-market competition
Piperacillin/tazobactam	Broader empiric coverage	Competes in serious polymicrobial infections

Cefotetan’s commercial opportunity is therefore concentrated in institutional protocols where its spectrum, dosing, or supply format justifies procurement.

What is the revenue exposure and launch outlook?

Revenue potential is moderate on a per-unit basis and depends on volume, contract access, and shortage dynamics. The product is unlikely to support premium pricing solely through the active ingredient. A differentiated ready-to-use presentation could command a higher net price if it reduces pharmacy labor or improves supply assurance.

Generic launch scenarios

Scenario	Expected market effect
Low-cost vial entrant	Price pressure with limited differentiation
Ready-to-use bag entrant	Share gain through pharmacy convenience
Room-temperature stable product	Distribution and inventory advantage
Shortage-period launch	Rapid demand capture but volatile volume
Dual-source hospital contract	Stable volume with lower unit margin
Premium packaging without workflow benefit	Limited uptake

The best commercial case combines an approved ready-to-use presentation, dependable supply, and purchasing contracts with hospitals and group purchasing organizations.

What geographic coverage matters for cefotetan?

United States value depends on FDA approval, National Drug Code distribution, hospital contracts, and supply history. European and other regulated markets require separate assessments of marketing authorization, pharmacopoeial standards, local tender systems, and antimicrobial stewardship policies.

Emerging-market opportunities may be larger in unit volume but face greater price pressure and variable regulatory enforcement. Local sterile manufacturing or regional fill-finish partnerships can improve tender competitiveness. Manufacturing-site qualification and API traceability remain essential in every jurisdiction.

Key Takeaways

• Cefotetan and dextrose injection is a mature generic IV antibiotic with no meaningful core-molecule exclusivity.
• Dextrose is the primary vehicle and tonicity component; the excipient system should remain simple and preservative-free where clinically appropriate.
• The strongest commercial opportunity is a ready-to-use, single-dose premixed bag that reduces pharmacy preparation.
• Formulation patents are most defensible when tied to demonstrated stability, container compatibility, impurity control, or delivery-device performance.
• Paragraph IV and patent-litigation risk is limited for the core product but can arise around new formulations and packaging systems.
• Biosimilar risk is not relevant because cefotetan is a small-molecule antibiotic.
• Revenue depends on hospital contracts, supply reliability, sterile-manufacturing capacity, and procurement economics.
• Competitive positioning against cefazolin, cefoxitin, ceftriaxone, and broader-spectrum agents must be based on institutional use protocols rather than molecule novelty.

FAQs

Is dextrose an active ingredient in cefotetan and dextrose injection?

No. Cefotetan is the antibacterial active ingredient. Dextrose is the vehicle and contributes to tonicity and carbohydrate content.

Can cefotetan and dextrose injection be reformulated with normal saline?

A saline presentation would be a separate formulation requiring compatibility, stability, labeling, and regulatory support. It should not be assumed to be equivalent to a dextrose-based product.

Is cefotetan and dextrose injection suitable for outpatient infusion?

It can be suitable where the approved product, storage conditions, administration instructions, and clinical protocol support outpatient use. Ready-to-use packaging improves outpatient workflow.

Can a new manufacturer obtain market exclusivity for cefotetan?

Core-drug exclusivity is unlikely. A manufacturer may obtain limited protection through formulation, container, device, process, or regulatory exclusivity associated with a qualifying new presentation.

What is the most valuable patent strategy for a new cefotetan infusion product?

The strongest strategy generally combines claims directed to a defined cefotetan-dextrose composition, a stability-supported storage condition, a compatible container-closure system, and a validated manufacturing process.

References

1. U.S. Food and Drug Administration. (2023a). Cefotetan for injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. DailyMed. (2024). Cefotetan and dextrose injection product labeling. National Library of Medicine.